TABLE 3.
Univariate and multivariate analyses of potential predictive factors of PFS.
| a Univariate analyses HR (95% CI) | p‐value | a Multivariate analyses HR (95% CI) | p‐value | b Univariate analyses HR (95% CI) | p‐value | b Multivariate analyses HR (95% CI) | p‐value | |
|---|---|---|---|---|---|---|---|---|
| Male | 1.59 (1.04, 2.44) | 0.0331 | 1.72 (1.09, 2.70) | 0.0187 | 2.69 (1.03, 7.03) | 0.0433 | 3.93 (1.38, 11.21) | 0.0106 |
| Age >60 years | 0.85 (0.60, 1.20) | 0.3542 | 0.99 (0.55, 1.78) | 0.9698 | ||||
| Smoking | 1.30 (0.91, 1.85) | 0.1453 | 1.97 (0.87, 4.48) | 0.1056 | ||||
| BMI <18.5 | 0.94 (0.58, 1.53) | 0.8120 | 1.21 (0.42, 3.47) | 0.7238 | ||||
| ECOG‐PS 2‐3 | 0.70 (0.40, 1.23) | 0.2094 | 0.56 (0.17, 1.83) | 0.3394 | ||||
| Other histological type | 1.50 (0.73, 3.08) | 0.2695 | 1.09 (0.34, 3.55) | 0.8830 | ||||
| Stage IV | 1.47 (0.88, 2.45) | 0.1400 | 1.47 (0.73, 2.99) | 0.2810 | ||||
| Brain metastases | 0.97 (0.62, 1.50) | 0.8811 | 1.78 (0.82, 3.83) | 0.1430 | ||||
| Contralateral lung metastases | 1.07 (0.76, 1.52) | 0.6894 | 1.10 (0.58, 2.06) | 0.7737 | ||||
| Pleural metastases | 1.19 (0.83, 1.72) | 0.3409 | 1.07 (0.56, 2.05) | 0.8322 | ||||
| Pericardial metastases | 1.12 (0.57, 2.21) | 0.7459 | 1.53 (0.21, 11.31) | 0.6770 | ||||
| Liver metastases | 1.53 (0.96, 2.46) | 0.0755 | 1.10 (0.64, 1.89) | 0.7389 | 2.10 (0.86, 5.11) | 0.1038 | ||
| Adrenal metastases | 1.52 (0.96, 2.42) | 0.0752 | 1.08 (0.64, 1.82) | 0.7641 | 1.78 (0.88, 3.59) | 0.1074 | ||
| Bone metastases | 1.26 (0.90, 1.78) | 0.1837 | 1.83 (0.97, 3.43) | 0.0612 | 1.78 (0.90, 3.53) | 0.0997 | ||
| Number of metastatic sites ≥2 | 1.79 (1.25, 2.55 | 0.0013 | 1.77 (1.19, 2.63) | 0.0045 | 2.96 (1.57, 5.58) | 0.0008 | 3.05 (1.55, 5.99) | 0.0012 |
| Taxanes ± platinum | 1.0 | 1.0 | 1.0 | 1.0 | ||||
| Pemetrexed ± platinum | 0.62 (0.38, 1.02) | 0.0617 | 0.63 (0.38, 1.06) | 0.0825 | 0.44 (0.16, 1.21) | 0.1117 | 0.43 (0.14, 1.25) | 0.1213 |
| Chemotherapy + antiangiogenesis/immunotherapies | 0.50 (0.28, 0.91) | 0.0222 | 0.49 (0.27, 0.91) | 0.0233 | 0.34 (0.12, 0.98) | 0.0466 | 0.24 (0.08, 0.75) | 0.0145 |
| KRAS WT | 1.0 | |||||||
| KRAS mutation | 0.94 (0.66, 1.35) | 0.7461 | ||||||
| KRAS G12C | 1.07 (0.55, 2.06) | 0.8443 | ||||||
| KRAS non‐G12C | 0.94 (0.54, 1.66) | 0.8422 |
Note: Independent variables with p < 0.10 in the univariate analyses were included in the Cox proportional hazards model. p values < 0.05 were highlighted in bold.
Abreviations: BMI, body mass index; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio; WT, wild‐type.
a
Univariate and multivariate analysis for PFS in all patients after first‐line treatment;
b
Univariate and multivariate analysis for PFS in KRAS‐mutated patients after first‐line treatment.